OWL is a biotechnology company in the field of Metabolomics with pioneering diagnostics products and unique R&D services for the scientific community.

Metabolomics uncovers metabolic alterations in biological samples and provides an overall picture of human or animal health: The information on complex biochemical processes obtained is highly valuable in drug mechanism and toxicology studies, biomarker discovery and the optimization of biotechnological processes.

OWL´s two business lines stem from our in depth knowledge of metabolomics and liver diseases.


"OWLiver Test" is the first "in vitro" test for determining steatosis and NASH.
The company also develops diagnostic markers research for high prevalence diseases.


OWL applies its expertise in metabolomics and lipidomics to provide services to the pharmaceutical, food and cosmetics industries, as well as research centers, biotech companies and CROs.


Company introduction

  • OWLiver - information for physicians - how it works
  • owl liver for patients - that is it - benefits - faqs
  • what is metabolomics - get to know owl technology



OWL Metabolomics will participate in the International Liver Congress 2017, the 52nd annual meeting of the European Association for the Study of the Liver.
This year´s participation includes 3 scientific abstracts and a mini workshop. The abstracts will focus on the elucitation of the mode of action of Aramchol, and on liquid biopsy for NAFLD diagnosis, staging and management, together with NASH subtype identification. The workshop program will highlight the use of metabolomics within NASH diagnosis in clinical trials, in type 2 diabetes mellitus and in bariatric surgery.




Metabolomics-based testing shown to improve the diagnosis and treatment of non-alcoholic fatty liver disease (NAFLD)
CIC bioGUNE and OWL Metabolomics identify two subtypes of NAFLD. The results of the newly-published study in Gastroenterology may lead to changes in the way NASH is diagnosed and treated. The study demonstrates that there are two main subtypes of NASH evolution (named "M" and "no-M") which differ by the type of hepatic lipid metabolism alteration; and that NASH "M" subtype has the same metabolomic profile as the MAT1A-KO mice. The administration of S- adenosylmethionine (SAMe) is effective for NASH treatment in MAT1A-KO mice, so SAMe could be useful for NASH treatment in "M" subtype patients.


OWL is a trading name of
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - Spain
Phone: +34 94 431 85 40
Fax: +34 94 431 71 40

With this web OWL intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a
qualified physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 04/06/2017

With the collaboration of: